LAW – Page 4 – Talk Bio

Relmada Therapeutics Explores Strategic Alternatives Following Discontinuation of Two Phase 3 Trials

9 months ago talkbio0Tagged CNS disorder, Metabolic Diseases, Phase 3 trials, REL-1017, Relmada, strategic alternatives

Relmada Therapeutics, Phase 3 trials, Strategic alternatives, REL-1017, REL-P11, Central nervous system diseases, Metabolic disorders

Relmada Therapeutics Reassesses Strategy Following Discontinuation of Two Phase 3 Trials for REL-1017

9 months ago talkbio0Tagged Clinical Trials, Drug Development, MDD, Phase 3 trials, REL-1017, Relmada, Strategic Options, Unipolar Depression

Relmada Therapeutics, REL-1017, Phase 3 trials, Major Depressive Disorder (MDD), strategic options, clinical trials, drug development

Merck’s Investigational ADC Zilovertamab Vedotin Enters Phase 3 with 100% Complete Response Rate in DLBCL Patients

9 months ago talkbio0Tagged Antibody-Drug Conjugates, Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Phase 2 trial, Phase 3 trial, Programs - Publication Format, ROR1 protein, human, vedotin, Zilovertamab

Zilovertamab Vedotin, Antibody-Drug Conjugate (ADC), Diffuse Large B-Cell Lymphoma (DLBCL), Phase 2 Trial, Phase 3 Trial, ROR1, Merck, waveLINE Program

BioAge Labs Halts Phase 2 Obesity Trial Due to Liver Safety Concerns Just Two Months After IPO

9 months ago talkbio0Tagged Azelaprag, BioAge Labs, concerns, Eli, Eli Lilly, IPO, liver safety, Obesity, Phase 2 trial

BioAge Labs, Phase 2 trial, obesity, liver safety concerns, azelaprag, Eli Lilly, tirzepatide, IPO

Healthcare M&A and IRA Price Negotiations: Key Trends to Watch Amidst Political Shifts

9 months ago talkbio0Tagged Acquisitions, Drug Industry, drug price, Healthcare M&A, Inflation, Ira (eukaryote), Mediation, Medicare, mergers, Negotiation Program, Prices, trends qualifier

Healthcare M&A, IRA Price Negotiations, Medicare Drug Price Negotiation Program, Inflation Reduction Act, Pharmaceutical Industry Trends, Mergers and Acquisitions Outlook 2024